Merck & Co., Inc. · NYSE
Boost ROI with automation, single-use systems, continuous processing and real-time analytics that reduce costs, accelerate purification, and improve yield and product quality.Dublin, Nov.
"Glycomics / Glycobiology - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global glycomics / glycobiology market was valued at US$1.8 billion in 2025 and is projected to reach US$4.5…
Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite launching a new trial.
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything.
"Cell Dissociation - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell dissociation market was valued at US$249.5 million in 2025 and is projected to reach US$587.4 million by 2032…
"Competent Cells - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global competent cells market was valued at US$1.7 billion in 2025 and is projected to reach US$3.2 billion by 2032…
"Electrophoresis Equipment and Supplies - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global electrophoresis equipment and supplies market was valued at US$2.2 billion in 2025 and is…
Tech stocks keep beating estimates and then selling off anyway, Apple just joined the club, and Wall Street analysts are busy reshuffling their ratings on everything from nuclear energy plays to insurance giants.
RAHWAY, N.J., November 03, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine)…
Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care (SOC) with a history of
A plain-language read on what may be behind the move: sector peers, related headlines and the macro backdrop. Free with an account.